<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Famotidine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Famotidine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Famotidine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8436" href="/d/html/8436.html" rel="external">see "Famotidine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12462" href="/d/html/12462.html" rel="external">see "Famotidine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F169927"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Acid Reducer Maximum Strength [OTC];</li>
<li>Acid Reducer [OTC];</li>
<li>Famotidine Maximum Strength [OTC];</li>
<li>Famotidine Orig St [OTC];</li>
<li>FT Acid Reducer Max Strength [OTC];</li>
<li>FT Acid Reducer [OTC];</li>
<li>Heartburn Relief Max St [OTC];</li>
<li>Heartburn Relief [OTC];</li>
<li>Pepcid;</li>
<li>Pepcid AC Maximum Strength [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866873"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Famotidine;</li>
<li>ALTI-Famotidine;</li>
<li>CO Famotidine;</li>
<li>Famotidine Omega W-O Preserv;</li>
<li>Famotidine Omega W-Preserv;</li>
<li>GMD-Famotidine;</li>
<li>JAMP Famotidine;</li>
<li>TEVA-Famotidine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1058659"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>
<li>
<span class="list-set-name">Histamine H<sub>2</sub> Antagonist</span></li></ul></div>
<div class="block don drugH1Div" id="F53462446"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Consider judicial use in neonatal population due to an association of H<sub>2</sub> blocker use and an increased incidence of necrotizing enterocolitis (NEC) in VLBW neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16390920']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16390920'])">Ref</a></span>) and a reported approximate sixfold increase in mortality, NEC, and infection (ie, sepsis, pneumonia, UTI) in VLBW neonates receiving ranitidine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22157140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22157140'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="05b14ead-ef6b-4183-a2bc-959084d4b9b7">Gastric acid suppression, GERD</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric acid suppression, GERD:</b>
<b>Note: </b>Routine use is not recommended in preterm neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29915158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29915158'])">Ref</a></span>). Oral: Initial: 0.5 mg/kg/dose once daily; if not effective, may increase to 1 mg/kg/dose once daily; in the trial, the minimum GA for inclusion was ≥32 weeks and no minimum PNA inclusion criteria; the youngest patient reported to receive the higher 1 mg/kg/dose was 1.3 months PNA (median: 3.7 months; range: 1.3 to 10.5 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12752346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12752346'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="664ec66a-a950-4199-ac26-0806130937ce">Stress ulcer prophylaxis, gastric acid suppression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stress ulcer prophylaxis, gastric acid suppression:</b> Limited data available: IV: 0.25 to 0.5 mg/kg/dose once daily has been used; some data have suggested that the lower dose of 0.25 mg/kg may have a less favorable pharmacodynamics profile (eg, duration of gastric pH &gt;4) than the higher 0.5 mg/kg dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11301560','lexi-content-ref-15828852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11301560','lexi-content-ref-15828852'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F169952"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d70158bf-5a0b-453d-9ae1-580dc5459992">Gastroesophageal reflux disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Suspension:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants &lt;3 months: 0.5 mg/kg/dose once daily for up to 8 weeks; if not effective after 2 weeks, increasing to 1 mg/kg/dose once daily has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12752346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12752346'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥3 months, Children, and Adolescents ≤16 years: Initial: 0.5 mg/kg/dose twice daily; maximum dose: 40 mg/dose; doses up to 1 mg/kg/dose twice daily have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12752346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12752346'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Tablets: Children and Adolescents ≥40 kg: 20 mg twice daily for up to 6 weeks; for esophagitis and accompanying symptoms due to GERD, may use 20 to 40 mg twice daily for up to 12 weeks</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &lt;3 months: Limited data available: 0.25 mg/kg/dose once daily; dosing based on a pharmacokinetic study which included 7 patients &lt;3 months who received IV famotidine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15828852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15828852'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months: Limited data available: Initial: 0.25 mg/kg/dose every 12 hours; maximum dose: 20 mg/dose; dosing based on a pharmacokinetic study which included 11 patients &gt;3 to 12 months who received IV famotidine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15828852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15828852'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Initial: 0.25 mg/kg/dose every 12 hours; maximum dose: 20 mg/dose; doses up to 0.5 mg/kg/dose every 12 hours have been reported</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe1d58d2-ab4b-4894-8e1a-b7218ca12e14">Heartburn, acid indigestion, or sour stomach</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heartburn, acid indigestion, or sour stomach</b> (OTC labeling): Children ≥12 years and Adolescents: Oral: 10 to 20 mg every 12 hours; dose may be taken 15 to 60 minutes before eating foods known to cause heartburn; maximum daily dose: 2 tablets/<b>day</b> (20 to 40 mg dependent upon OTC product)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fe1c098-0767-49b7-87df-f3a4952757ba">Pathological hypersecretory conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pathological hypersecretory conditions (eg, Zollinger-Ellison):</b> Adolescents ≥17 years:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Initial: 20 mg every 6 hours, may increase up to 160 mg every 6 hours</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 20 mg every 12 hours</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2af7f7c-17b6-4ce5-b3f8-76af48f85574">Peptic ulcer disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peptic ulcer disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Suspension: Children and Adolescents ≤16 years: 0.5 mg/kg/<b>day</b> at bedtime or divided twice daily; maximum daily dose: 40 mg/<b>day</b>; doses up to 1 mg/kg/<b>day</b> at bedtime or divided twice daily have been used</p>
<p style="text-indent:-2em;margin-left:6em;">Tablets: Children and Adolescents &gt;40 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Duodenal ulcer: Acute therapy: 40 mg once daily at bedtime <b>or</b> 20 mg twice daily for 4 to 8 weeks</p>
<p style="text-indent:-2em;margin-left:8em;">Gastric ulcer: Acute therapy: 40 mg once daily at bedtime for up to 8 weeks</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Children and Adolescents: Initial: 0.25 mg/kg/dose every 12 hours; maximum dose: 20 mg/dose; doses up to 0.5 mg/kg/dose every 12 hours have been reported</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="664ec66a-a950-4199-ac26-0806130937ce">Stress ulcer prophylaxis, gastric acid suppression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stress ulcer prophylaxis, gastric acid suppression:</b> Limited data available: Infants, Children, and Adolescents: IV: 1 to 2 mg/kg/<b>day</b> in divided doses every 8 to 12 hours; maximum daily dose: 40 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9623009','lexi-content-ref-10690219','lexi-content-ref-7917695','lexi-content-ref-2311331','lexi-content-ref-2019939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9623009','lexi-content-ref-10690219','lexi-content-ref-7917695','lexi-content-ref-2311331','lexi-content-ref-2019939'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109829"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing is based on pharmacokinetic parameters, limited pediatric studies, adult studies, and expert opinion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007','lexi-content-ref-2902874','lexi-content-ref-12520622','lexi-content-ref-2861096','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007','lexi-content-ref-2902874','lexi-content-ref-12520622','lexi-content-ref-2861096','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Weight-based dosing: </b>Infants ≥3 months, Children, and Adolescents: IV, Oral:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Famotidine Dosage Adjustments in Altered Kidney Function (Weight-Based Dosing)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl</p></th>
<th align="center">
<p style="text-indent:0em;">Based on usual dose of 0.25 mg/kg/dose every 12 hours</p></th>
<th align="center">
<p style="text-indent:0em;">Based on usual dose of 0.5 mg/kg/dose every 12 hours</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">≥50 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to &lt;50 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">0.25 mg/kg/dose every 24 hours. Maximum dose: 10 mg/dose.</p></td>
<td align="center">
<p style="text-indent:0em;">0.5 mg/kg/dose every 24 hours. Maximum dose: 20 mg/dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;10 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">0.125 mg/kg/dose every 24 hours. Maximum dose: 5 mg/dose.</p></td>
<td align="center">
<p style="text-indent:0em;">0.25 mg/kg/dose every 24 hours. Maximum dose: 10 mg/dose.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Fixed dosing:</b> Children and Adolescents weighing ≥40 kg: Oral:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Famotidine Dosage Adjustments in Altered Kidney Function (Fixed Dosing)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl</p></th>
<th align="center">
<p style="text-indent:0em;">Based on usual dose of 10 mg twice daily</p></th>
<th align="center">
<p style="text-indent:0em;">Based on usual dose is 20 mg once daily</p></th>
<th align="center">
<p style="text-indent:0em;">Based on usual dose is 20 mg twice daily</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">CrCl ≥60 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">CrCl 30 to &lt;60 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">10 mg once daily <b>or</b> 20 mg every other day</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg once daily <b>or</b> 20 mg every other day</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg once daily <b>or</b> 40 mg every other day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">10 mg every other day</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg every other day</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg once daily <b>or</b> 20 mg every other day</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (~6% to 16%):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents: IV, Oral: Dose as for CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>; administer after hemodialysis on hemodialysis days. No supplemental dose necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Minimally dialyzed (CAPD ~5%):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents: IV, Oral: Dose as for CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b>
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and standard effluent flow rates of 25 to 40 mL/kg/hour (~2,000 to 3,000 mL/1.73 m<sup>2</sup>/hour).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents: IV, Oral: Dose as for CrCl 10 to &lt;50 mL/minute/1.73 m<sup>2</sup>.</p></div>
<div class="block dohp drugH1Div" id="F51109830"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F169931"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8436" href="/d/html/8436.html" rel="external">see "Famotidine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9e2fd80-308d-4eb0-a497-00b0397cb8b3">Aspiration prophylaxis in patients undergoing anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspiration prophylaxis in patients undergoing anesthesia (off-label use): Note:</b> May be considered in patients at high risk for aspiration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26580836','lexi-content-ref-Berkow.2019','lexi-content-ref-Hagberg.2019','lexi-content-ref-20562638','lexi-content-ref-11692973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26580836','lexi-content-ref-Berkow.2019','lexi-content-ref-Hagberg.2019','lexi-content-ref-20562638','lexi-content-ref-11692973'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 20 mg as a single dose ~40 to 90 minutes prior to induction of anesthesia; may be given with a rapid-acting nonparticulate antacid (eg, oral sodium citrate and citric acid) and/or metoclopramide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Abir.2022','lexi-content-ref-26580836','lexi-content-ref-28045707','lexi-content-ref-Berkow.2019','lexi-content-ref-2872952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Abir.2022','lexi-content-ref-26580836','lexi-content-ref-28045707','lexi-content-ref-Berkow.2019','lexi-content-ref-2872952'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="57b2690d-2e6b-47ae-87e7-f6f5ed2ef93f">Erosive esophagitis due to gastroesophageal reflux disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erosive esophagitis due to gastroesophageal reflux disease (alternative agent): Note: </b>Although a labeled indication, H<sub>2</sub>-receptor antagonists (eg, famotidine) are not preferred for the treatment of erosive esophagitis due to gastroesophageal reflux disease due to the availability of proton pump inhibitors (PPIs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34807007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34807007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 or 40 mg twice daily for up to 12 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (alternative route):</b> 20 mg every 12 hours. <b>Note:</b> For use when oral therapy is not appropriate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="453d2aa1-ad96-4b87-b798-62f67b898c2e">Gastroesophageal reflux disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Mild and intermittent symptoms (&lt;2 episodes/week), and no evidence of erosive esophagitis: Note: </b>For more severe or frequent initial symptoms, with or without evidence of erosive esophagitis, a proton pump inhibitor (PPI) as initial therapy is recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 10 mg twice daily as needed; if symptoms persist after 2 to 4 weeks, increase to 20 mg twice daily for 2 weeks; if symptoms improve, may continue therapy as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-kahrilas.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-kahrilas.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If symptoms persist after 2 weeks of 20 mg twice daily, discontinue and consider PPI therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-kahrilas.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-kahrilas.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Residual acid reflux symptoms despite maximal PPI therapy (adjunct):</i></b>
<b>Oral:</b> 20 mg once daily given at bedtime in addition to PPI therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23419381','lexi-content-ref-19821323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23419381','lexi-content-ref-19821323'])">Ref</a></span>); may also administer famotidine intermittently or on demand with scheduled PPI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-fass.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-fass.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>OTC labeling (patient-guided therapy): </i></b>Heartburn, mild intermittent symptoms: <b>Oral:</b> 10 to 20 mg up to twice daily when needed (maximum: 40 mg/day); may also be taken 10 to 60 minutes before meals or beverages that cause heartburn (maximum: 40 mg/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b0617bcf-4c72-4048-820f-7cedee1ad687">Infusion reaction, premedication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion reaction, premedication (adjunct) (off-label use): IV, Oral:</b> 20 mg typically administered 30 to 60 minutes prior to infusion of certain chemotherapy agents or biologics; usually given in conjunction with an H<sub>1</sub> antihistamine (eg, diphenhydramine) and glucocorticoid (refer to institutional protocols) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Castells.2019.b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Castells.2019.b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ce76507-f86c-4c5d-9b8f-c438b26b8e58">Mastocytosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mastocytosis (adjunct) (off-label use): Oral:</b> 10 to 20 mg every 12 hours adjusted to achieve GI symptom relief. Typically used in combination with other appropriate agent(s) (eg, H<sub>1</sub> antihistamine and/or leukotriene inhibitor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Akin.2019','lexi-content-ref-Castells.2019.a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Akin.2019','lexi-content-ref-Castells.2019.a'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fe1c098-0767-49b7-87df-f3a4952757ba">Pathological hypersecretory conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome [gastrinoma])</b> (alternative agent): <b>Note:</b> Although a labeled indication, clinical experience suggests that H<sub>2</sub>-receptor antagonists (eg, famotidine) are not preferred for controlling acid hypersecretion in pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome) due to the availability of PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29019150','lexi-content-ref-23363383','lexi-content-ref-16222731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29019150','lexi-content-ref-23363383','lexi-content-ref-16222731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 20 mg every 6 hours; may adjust dose based on patient response (maximum: 640 mg/day [160 mg every 6 hours]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (alternative route):</b> 20 mg every 12 hours; higher doses may be required. <b>Note:</b> For use when oral therapy is not appropriate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2af7f7c-17b6-4ce5-b3f8-76af48f85574">Peptic ulcer disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peptic ulcer disease (duodenal or gastric ulcers) (alternative agent):</b>
<b>Note:</b> Although a labeled indication, current guidelines recommend PPIs as standard of care for treatment of peptic ulcer disease rather than H<sub>2</sub>-receptor antagonists (eg, famotidine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duodenal ulcer:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 40 mg once daily or 20 mg twice daily for up to 8 weeks; maintenance therapy: 20 mg once daily for 1 year or as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV (alternative route):</b> 20 mg every 12 hours. <b>Note:</b> For use when oral therapy is not appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Gastric ulcer:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral</b>: 40 mg once daily for up to 8 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV (alternative route):</b> 20 mg every 12 hours. <b>Note:</b> For use when oral therapy is not appropriate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ddad78db-4422-47a9-8299-1c11f40d1828">Stress ulcer prophylaxis in select critically ill patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stress ulcer prophylaxis in select critically ill patients </b>
<b>(alternative agent) (off-label use):</b>
<b>Note:</b> Used as an alternative for proton pump inhibitors in critically ill patients with risk factors for GI bleeding (eg, coagulopathy, mechanical ventilation for &gt;48 hours, traumatic brain injury, history of GI ulceration or bleeding within past year, extensive burns) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b>
<b>or via nasogastric (NG) tube</b> (alternative to enteral PPI): 20 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10690219','lexi-content-ref-Weinhouse.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10690219','lexi-content-ref-Weinhouse.2022'])">Ref</a></span>). Discontinue prophylaxis once risk factors have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 20 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10690219','lexi-content-ref-Weinhouse.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10690219','lexi-content-ref-Weinhouse.2022'])">Ref</a></span>). Discontinue prophylaxis once risk factors have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e59a61ec-4a7a-40f9-83a5-0a8d439e15d5">Urticaria, chronic spontaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, chronic spontaneous (alternative agent) (adjunct) (off-label use): Note:</b> Use as additional therapy if insufficient response to full-dose H<sub>1</sub> antihistamine.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 mg twice daily given in combination with H<sub>1</sub> antihistamine; a trial of 2 to 4 weeks is suggested to assess response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-kahn.2019','lexi-content-ref-27690471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-kahn.2019','lexi-content-ref-27690471'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991774"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1764869','lexi-content-ref-2861096','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1764869','lexi-content-ref-2861096','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;50 mL/minute: Administer 50% of usual dose <b>or</b> continue usual dose but increase the dosing interval to every 36 to 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Famotidine Oral Dosage Adjustments in Altered Kidney Function</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl (mL/minute)</p></th>
<th align="center">
<p style="text-indent:0em;">If usual dose is 10 mg twice daily</p></th>
<th align="center">
<p style="text-indent:0em;">If usual dose is 20 mg once daily</p></th>
<th align="center">
<p style="text-indent:0em;">If usual dose is 20 mg twice daily</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">CrCl ≥60</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">CrCl 30 to &lt;60</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg once daily or 20 mg every other day</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg once daily or 20 mg every other day</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg once daily or 40 mg every other day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">CrCl &lt;30</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg every other day</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg every other day</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg once daily or 20 mg every other day</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (6% to 16%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2902874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2902874'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> Dose as for CrCl &lt;30 mL/minute; administer after hemodialysis on dialysis days. No supplemental dose necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2902874','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2902874','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Minimally dialyzed (5%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2902874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2902874'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> Dose as for CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Limited data utilizing hemofiltration rates of ≤1,800 mL/hour did not demonstrate a dose reduction is necessary (Saima 1990); however, no data regarding famotidine disposition utilizing contemporary flow rates of up to ~3,000 mL/hour are available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> Dose as for CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> Dose as for CrCl &lt;30 mL/minute; administer post-PIRRT session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988925"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F55986929"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">CNS effects have been reported with famotidine and may include <b>agitation</b>, <b>confusion</b>, and <b>delirium</b> (among others). These effects appear to be reversible with discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8701013','lexi-content-ref-3243179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8701013','lexi-content-ref-3243179'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; may occur due to increased central anticholinergic action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1674198','lexi-content-ref-4030706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1674198','lexi-content-ref-4030706'])">Ref</a></span>). There is no evidence to support a difference among agents in the H<sub>2</sub>-receptor antagonist class (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1674198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1674198'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; in case reports, CNS effects occurred within 2 to 6 days of IV famotidine initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8701013','lexi-content-ref-3243179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8701013','lexi-content-ref-3243179'])">Ref</a></span>) and within the first 2 to 3 weeks of oral famotidine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1674198','lexi-content-ref-8701013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1674198','lexi-content-ref-8701013'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors :</i></p>
<p style="text-indent:-2em;margin-left:6em;">For H<sub>2</sub>-receptor antagonists in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Age ≥60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1674198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1674198'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hospitalization, especially ICU (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1674198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1674198'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney or liver impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1674198','lexi-content-ref-8004885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1674198','lexi-content-ref-8004885'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Necrotizing enterocolitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">H<sub>2</sub>-receptor antagonists, including famotidine, may be associated with an increased incidence of <b>necrotizing enterocolitis</b> in very low birth weight (VLBW) neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29915158','lexi-content-ref-16390920','lexi-content-ref-27390109','lexi-content-ref-30947259','lexi-content-ref-22157140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29915158','lexi-content-ref-16390920','lexi-content-ref-27390109','lexi-content-ref-30947259','lexi-content-ref-22157140'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; possibly due to an increase in gastric pH, which alters the intestinal microbiome and weakens the protective barrier against bacterial overgrowth in the premature gut (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29915158','lexi-content-ref-23254444','lexi-content-ref-27390109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29915158','lexi-content-ref-23254444','lexi-content-ref-27390109'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• VLBW neonates (&lt;1,500 grams) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16390920']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16390920'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of treatment (median duration of exposure: 10 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27390109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27390109'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prematurity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16390920']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16390920'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombocytopenia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thrombocytopenia</b> has been reported rarely with IV and oral famotidine and may increase the risk of bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22273212','lexi-content-ref-15557833','lexi-content-ref-8193440','lexi-content-ref-11967601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22273212','lexi-content-ref-15557833','lexi-content-ref-8193440','lexi-content-ref-11967601'])">Ref</a></span>). Most patients who developed thrombocytopenia while receiving an H<sub>2</sub>-receptor antagonist also had at least one documented independent risk factor for thrombocytopenia (eg, age, sepsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15557833','lexi-content-ref-11967601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15557833','lexi-content-ref-11967601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; postulated to occur secondary to one of two mechanisms: Induction of bone marrow suppression secondary to inhibition of DNA synthesis or development of platelet antibodies during H<sub>2</sub>-receptor antagonist administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11967601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11967601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; in case reports with H<sub>2</sub>-receptor antagonists, average onset: 14 days (range: 1 to 75 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11967601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11967601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher injury severity scores (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22273212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22273212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer length of hospitalization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22273212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22273212'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F169894"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. All reported ADRs are for the oral formulations unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Agitation (infants)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (1%), diarrhea (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1%), headache (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, anorexia, nausea, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, depression, drowsiness, fatigue, hallucination, insomnia, seizure (von Einsiedel 2002), taste disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, asthenia, musculoskeletal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival injection, periorbital edema</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Local: Irritation at injection site (IV)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block (Schoenwald 1999), cardiac arrhythmia (Ahmad 1991), facial edema, prolonged QT interval on ECG (Lee 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome, toxic epidermal necrolysis (Brunner 1995), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Necrotizing enterocolitis (very low birth weight neonates; Guillet 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Marcus 2002), leukopenia, neutropenia (Oymak 1994), pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatitis (Gupta 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Kim 2010), angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Wu 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion, delirium (Catalano 1996), disorientation (Rodgers 1998; Yoshimoto 1994), mania (von Einsiedel 2002), nightmares (Rodgers 1998), paresthesia, restlessness (Rodgers 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (Hirayama 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis</p></div>
<div class="block coi drugH1Div" id="F169907"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serious hypersensitivity (eg, anaphylaxis) to famotidine, other H<sub>2</sub> antagonists, or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication (OTC), do not use if trouble or pain when swallowing food, vomiting with blood, or bloody or black stools; allergic to other acid reducers; kidney impairment; coadministration with other acid reducers.</p></div>
<div class="block war drugH1Div" id="F169891"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects.</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin B<sub>12</sub> deficiency: Famotidine and other H2RAs can reduce absorption of vitamin B<sub>12</sub> and thus decrease serum concentrations. It is unclear of its role in causing function or clinical deficiencies . A number of studies have tried to determine the association of B<sub>12</sub> deficiency with H2RAs use; however, differences in diagnostic criteria have made this challenging (Miller 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution; increased risk of QT prolongation; dosage adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• OTC labeling: When used for self-medication (OTC), notify health care provider before use if any of the following are present: Frequent chest pain; frequent wheezing particularly with heartburn; nausea/vomiting; unexplained weight loss; stomach pain; heartburn &gt;3 months; heartburn with light-headedness, sweating, or dizziness; chest pain or shoulder pain with shortness of breath; sweating; pain that spreads to arms, neck, or shoulders; light-headedness. Discontinue use and notify health care provider if heartburn continues or worsens, or if use is required &gt;14 days.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878451"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients 4 to 36 months of age (Canani 2006). A large epidemiological study has suggested an increased risk for developing pneumonia in patients receiving H<sub>2</sub> receptor antagonists; however, a causal relationship with famotidine has not been demonstrated. An approximate sixfold increase in mortality, necrotizing enterocolitis, and infection (ie, sepsis, pneumonia, urinary tract infection) was reported in patients receiving ranitidine in a cohort analysis of 274 very low birth weight neonates (Terrin 2012). Routine use of H<sub>2</sub> blockers in preterm infants is not recommended (AAP [Eichenwald 2018]).</p></div>
<div class="block foc drugH1Div" id="F169901"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg (50 mL); 40 mg/4 mL (4 mL); 200 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg/5 mL (50 mL, 100 mL, 150 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acid Reducer: 10 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acid Reducer Maximum Strength: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Famotidine Maximum Strength: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Famotidine Orig St: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Acid Reducer: 10 mg [gluten free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Acid Reducer Max Strength: 20 mg [gluten free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Heartburn Relief: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Heartburn Relief Max St: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pepcid: 20 mg, 40 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pepcid AC Maximum Strength: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg</p></div>
<div class="block geq drugH1Div" id="F169887"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F169909"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Famotidine (PF) Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/2 mL (per mL): $0.44 - $0.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Famotidine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/4 mL (per mL): $0.53 - $0.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/20 mL (per mL): $0.53 - $0.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Famotidine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/5 mL (per mL): $3.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Famotidine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.12 - $0.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.06 - $2.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.08 - $4.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pepcid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $15.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $30.67</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866874"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (2 mL, 4 mL, 5 mL, 20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg</p></div>
<div class="block exp drugH1Div" id="F11368091"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> A famotidine suspension (8 mg/mL) is commercially available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>8 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:2em;">An 8 mg/mL oral suspension may be made with tablets. Crush seventy 40 mg tablets in a mortar and reduce to a fine powder. Add small portions of sterile water and mix to a uniform paste. Mix while adding a 1:1 mixture of Ora-Plus and Ora-Sweet in incremental proportions to <b>almost</b> 350 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 350 mL. Label "shake well." Stable for 95 days at room temperature.</p>
<div class="reference">Dentinger PJ, Swenson CF, Anaizi NH. Stability of famotidine in an extemporaneously compounded oral liquid. <i>Am J Health Syst Pharm.</i> 2000;57(14):1340-1342.<span class="pubmed-id">10918924</span></div>
</div>
<div class="block admp drugH1Div" id="F52612807"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer with antacids. May be taken without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Shake vigorously for 10 to 15 seconds prior to each use</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet (OTC): Do not chew; dose may be taken 10 to 60 minutes before eating food or drinking beverages known to cause heartburn</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: May be administered at a rate of ≤10 mg/minute over at least 2 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion: Infuse over 15 to 30 minutes</p></div>
<div class="block adm drugH1Div" id="F169904"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV push:</b> Administer over at least 2 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Solution for infusion:</b> Administer over 15 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to meals. May administer with antacids.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Shake vigorously before use.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet (OTC): To prevent symptoms, administer 10 to 60 minutes before eating food or drinking beverages known to cause heartburn.</p></div>
<div class="block sts drugH1Div" id="F169921"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Powder for oral suspension: Prior to reconstitution, store at 25°C (77°F). Reconstituted oral suspension is stable for 30 days at room temperature; do not freeze.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Solution for injection: Prior to use, store at 2°C to 8°C (36°F to 46°F). If solution freezes, allow to solubilize at room temperature.</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: Following preparation, solutions for IV push should be used immediately, or may be stored in refrigerator and used within 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Infusion: Following dilution in D5W, D10W, NS or LR, may be stored for up to 48 hours under refrigeration; however, solutions for infusion have been found to be physically and chemically stable for 7 days at room temperature (maintains at least 90% of initial potency).</p>
<p style="text-indent:-2em;margin-left:4em;">Solution for injection, premixed bags: Store at 25°C (77°F); avoid excessive heat.</p></div>
<div class="block usep drugH1Div" id="F53566863"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Prescription products: Short-term treatment for GERD (FDA approved in all ages); short-term treatment of active duodenal ulcer and maintenance therapy after healing of active ulcer (FDA approved in ages ≥1 year and adults); short-term treatment of active benign gastric ulcer (FDA approved in ages ≥1 year and adults); treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas) (FDA approved in ages ≥17 years and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">OTC products: Relief of heartburn, acid indigestion, and sour stomach (FDA approved in ages ≥12 years and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Has also been used for symptomatic relief in gastritis</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Short-term therapy and treatment for GERD, duodenal ulcer, and active benign gastric ulcer until oral famotidine therapy can be initiated (FDA approved in ages 1 to 16 years and adults); treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas) until oral famotidine therapy can be initiated (FDA approved in ages ≥17 years and adults); has also been used for stress ulcer prophylaxis and gastric acid suppression in critically ill patients</p></div>
<div class="block mst drugH1Div" id="F7305905"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Famotidine may be confused with FLUoxetine, furosemide</p>
<p style="text-indent:-2em;margin-left:4em;">Zantac 360 may be confused with Zantac (former brand name for ranitidine)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299312"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3, OCT1</p></div>
<div class="block dri drugH1Div" id="F169896"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib.  Management: Give acalabrutinib capsules 2 hours before a histamine H2 receptor antagonist (H2RA). No action is required if acalabrutinib tablets are coadministered with H2RAs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Histamine H2 Receptor Antagonists may decrease the serum concentration of Belumosudil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists (H2RAs) more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dacomitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Dacomitinib.  Management: Administer dacomitinib at least 6 hours before or 10 hours after an histamine H2-receptor antagonist (H2RA).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Delavirdine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: May increase the serum concentration of Famotidine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxacin: Histamine H2 Receptor Antagonists may decrease the absorption of Enoxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or 6 hours after administration of a histamine H2 receptor antagonist (H2RA), and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Histamine H2 Receptor Antagonists may decrease serum concentrations of the active metabolite(s) of Infigratinib. Histamine H2 Receptor Antagonists may decrease the serum concentration of Infigratinib.  Management: Avoid coadministration of infigratinib with histamine receptor antagonists (H2RAs) or other gastric acid-lowering agents. If H2RAs cannot be avoided, administer infigratinib 2 hours before or 10 hours after administration of H2RAs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Histamine H2 Receptor Antagonists may increase the serum concentration of Itraconazole. Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole.  Management: Administer Sporanox brand itraconazole at least 2 hours before or 2 hours after administration of any histamine H2 receptor antagonists (H2RAs). Exposure to Tolsura brand itraconazole may be increased by H2RAs; consider itraconazole dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Histamine H2 Receptor Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer ketoconazole with an acidic beverage (eg, non-diet cola) and monitor for reduced efficacy if concomitant use with a H2RA is required. Increases in ketoconazole dose may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir.  Management: Administer H2 receptor antagonist doses less than or comparable to famotidine 40 mg twice daily simultaneously or 12 hours prior to ledipasvir. The effect of administering H2 receptor antagonists at other time intervals is unknown and  not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Histamine H2 Receptor Antagonists may decrease the absorption of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Histamine H2 Receptor Antagonists may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Histamine H2 Receptor Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption.  Management: Administer neratinib at least 2 hours before or 10 hours after administration of a histamine H2 receptor antagonist to minimize the impact of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib.  Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Histamine H2 Receptor Antagonists may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Pexidartinib.  Management: Administer pexidartinib 2 hours before or 10 hours after histamine H2 receptor antagonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Posaconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists (H2RAs) at least 12 hours before or 4 hours after oral rilpivirine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risedronate: Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir.  Management: Consider alternatives to this combination for patients taking the Invirase formulation of saquinavir. No action beyond standard clinical care measures is required for patients taking the Fortovase formulation of saquinavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and H2 receptor antagonists should be avoided. If coadministration cannot be avoided, selpercatinib should be administered 2 hours before or 10 hours after H2 receptor antagonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Histamine H2 Receptor Antagonists may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Velpatasvir. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F169924"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Prolonged treatment (≥2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam 2013).</p></div>
<div class="block pri drugH1Div" id="F169910"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Famotidine crosses the placenta (Wang 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, renal clearance of famotidine may be increased (Wang 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Histamine H<sub>2</sub> antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD) during pregnancy. Agents other than famotidine may be preferred for initial therapy (Richter 2005; van der Woude 2014). Histamine H<sub>2</sub> antagonists may be used for aspiration prophylaxis prior to cesarean delivery (ASA 2016).</p></div>
<div class="block mopp drugH1Div" id="F53566861"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, gastric pH, occult blood with GI bleeding; renal function</p></div>
<div class="block pha drugH1Div" id="F169890"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitive inhibition of histamine at H<sub>2</sub> receptors of the gastric parietal cells, which inhibits gastric acid secretion</p></div>
<div class="block phk drugH1Div" id="F169906"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Antisecretory effect: Oral: Within 1 hour</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Antisecretory effect: Oral: Within 1 to 3 hours (dose-dependent); IV: Within 30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Antisecretory effect: IV, Oral: 10 to 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Incompletely absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: ≤3 months: 1.4 ± 0.4 L/kg to 1.8 ± 0.3 L/kg; &gt;3 to 12 months: 2.3 ± 0.7 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;11 years: 2.07 ± 1.49 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥11 years and Adolescents ≤15 years: 1.5 ± 0.4 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1.3 ± 0.2 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 15% to 20%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: 30% to 35%; minimal first-pass metabolism; forms one metabolite (S-oxide)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 40% to 45%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: ≤3 months: 8.1 ± 3.5 hours to 10.5 ± 5.4 hours; &gt;3 to 12 months: 4.5 ± 1.1 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;11 years: 3.38 ± 2.6 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥11 years and Adolescents ≤15 years: 2.3 ± 0.4 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 2.5 to 3.5 hours; prolonged with kidney impairment; Oliguria: &gt;20 hours; Anuria: 24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: ~1 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (25% to 30% [oral], 65% to 70% [IV] as unchanged drug)</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: ≤3 months: 0.13 ± 0.06 to 0.21 ± 0.06 L/hour/kg; &gt;3 to 12 months: 0.49 ± 0.17 L/hour/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;11 years: 0.54 ± 0.34 L/hour/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥11 years and Adolescents ≤15 years: 0.48 ± 0.14 L/hour/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.39 ± 0.14 L/hour/kg</p></div>
<div class="block phksp drugH1Div" id="F51807180"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC increased at least 5-fold and at least 2-fold in adults with CrCl &lt;30 mL/minute and CrCl 30 to 60 mL/minute, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F169913"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Antodine | Asiamodin | Famodar | Famotec | Pepcidin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Gastrosedol nf | Taural f | Ulfam</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Famohexal | Famosin | Famotidin genericon pharma | Famotidin interpharm | Famotidin ratiopharm | Famotidin stada artzneimittel | Sodexx famotidin | Ulcusan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amfamox | Ausfam | Chemmart famotidine | Cm famotidine | Famohexal | Famotidine an | Famotidine Pfizer | Famotidine sandoz | Pamacid | Pepcidine | Pepzan | Tw famotidine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Axidin | Famo | Famodin | Famogen | Famoj | Famotab | Famotack | Famote | Famotid | Famotin | Nacid | Nocid | Novatac | Peptid | Servipep | Yamadin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Pepcidine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Famosan | Famotidin | Famotidine Alkaloid | Famotidine Sopharma | Famultran | Quamatel | Ulceran</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Asid | Famodine | Famoset | Famotid | Famotil | Famox | Famoxil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Pepcidine</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Anulbet | Famotidina | Fibonel | Gastrium</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An wei te | Bei lan de | Bin xin | Bo la kang wei | Duo yi | Gaster | Jie ke da | Luo ke | Xin fa ding | Yi jie fa</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ciclonal | Dibrit | Famogal | Famoter | Famotid | Famotidina | Famotidina mk | Farmotex | Fenox | Gastrosal | Gastrum | Pepcidine | Phamotin | Ulfadin | Ulfagel</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">APO Famotidine | Famosan | Famotidin | Quamatel | Ulceran | Ulfamid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fadul | Famo | Famo abz | Famobeta | Famonerton | Famotidin | Famotidin 1a pharma | Famotidin klast | Famotidin milinda | Famotidin von ct | Ganor | Pepdine | Pepdul</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dinasil | Durater | Famopep | Famotidina | Famotin | Famoxal | Famulcer | Finitacid | Framodina | Gasduo | Gastril | Gastrodomina | Gastropep | Lazzuril | Nocidex | Nor-Famotidina | Pepcid | Peptril | Rubacina | Ulcefan | Ulfacaps</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Famotax | Famotec | Famotidina | Fibonel | It-Famochem | Pepcidine | Ulcelac | Ulfagel</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Famosan | Famotidin | Famotidin ratiopharm | Famotidin stada | Quamatel | Ulcusan | Ulfamid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Antodine | Famotak | Famotin | Gastrodomina | Gastrotidine | Peptec | Servipep | Ulcetech | Ulfamide</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Brolin | Confobos | Cronol | Digervin | Eviantrina | Fagastril | Famokey | Famotidina bayvit | Famotidina Cinfa | Famotidina edigen | Famotidina esteve | Famotidina mabo | Famotidina normon | Famotidina Ranbaxy | Famotidina ratiopharm | Famulcer | Fanox | Gastenin | Gastrion | Gastrodomina | Ingastri | Nos | Nulcerin | Pepcid | Rubacina | Tairal | Tameran | Tamin | Tipodex | Ulcetrax | Ulgarine | Vagostal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Famotidin hexal | Famotidin ratiopharm | Pepcid | Pepcidin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Famotidine Dci | Famotidine eg | Famotidine g gam | Famotidine merck | Pepcidac | Pepdine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Famotidine arrow | Famotidine kent | Famotidine sandoz | Pepcid | Pepcid ac</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ansilan | Banatin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">APO Famotidine | Axcel Famotidine | Bf-Famotidine | Cosodine | Facid | Fad | Fadine | Famine | Famodine | Famol | Famolta | Famopsin | Famosia | Famotab | Famotin | Famox | Famoxine | Famtine | Gastrodomina | Interfam | Keamotin | Marmodine | Motidine | Novo-famotidine | Pecodine | Pepcidine | Pepzan | Peradine | Phyzidine | Quamatel | Servipep | Sunpepcin | U famodine | Ulance | Ularance | Ulcedine | Ulceran | Uni-Cidine | Vickmodine | Vida-Famodine | Winiful</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Famosan | Ulfamid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Apo-famotidin | Famotidin 1 A Pharma | Famotidin hexal | Motidin | Peptigal | Quamatel | Servipep | Ulfamid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Antidine | Corocyd | Denufam | Faberdin | Facid | Famocid | Famos | Fluktan | Gasfamin | Gaster | Gestofam | Hacip | Hufatidine | Incifam | Interfam | Lexmodine | Mecofam | Mosul | Motipep | Nulcefam | Pompaton | Pratifar | Purifam | Regastin | Renapepsa | Restadin | Tismafam | Ulcatif | Ulcerid | Ulfam | Ulmo</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Acidopine | Pepcid | Pepcid ac</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Apogastine | Famo | Famotidine Teva | Gastro | Rogasti</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acicon | Acilo | Acredin | Autidine | Cocid | Facid | Fadine | Faltidin | Fam-h2 | Famaldin | Famcool | Famocid | Famodil | Famodin | Famolink | Famolite | Famonext | Famonite | Famopril | Famorila | Famot | Famotidine fc | Famotin | Famovane | Famowal | Fampep | Famtac | Febcid | Fendin | Fidine | Fintin | Fm | Fudone | Fudone-pm | Noctin | Pepdin | Peptac | Stacid | Temcid | Topcid | Ulcimax | Ulfamo | Zactane</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Famosam</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Famodil | Famotidina eg | Gastridin | Motiax</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Acifam | Amodine | Famodar | Famodine | Gastrifam | Pepcidin | Peptifam | Stomax | Ulceran</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bessen h2 | Famogast | Famogast chemiphar | Famotidine d emec | Famotidine isei | Famotidine sawai | Gamofa | Gascept | Gasdock | Gasmet | Gasport | Gaster | Gasuisan | Momiaron | Tiostar</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Yamadin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acidcon | Amotin | Bearfamo | Bemodine | Bestidine | Bm famotidine | Choa famotidine | Cufarin | Dae hwa famotidine | Evatin | Fagastine | Famagen | Famcid | Famedine | Famertidine | Famidine | Famitin | Famo q | Famo queen | Famocan | Famodine | Famolex | Famoline | Famona | Famondin | Famorjine | Famorodine | Famos | Famoster | Famostin | Famota | Famotan | Famoten | Famoter | Famotican | Famotidine daewha | Famotine | Famotop | Famowitun | Famozen | Famtidine | Famtin | Fapotin | Fararidin | Farmost | Farmoti m | Fatak | Fatimone | Femodine | Ferotine | Fontyna | Gardin | Gasfamo | Gaspamo | GL famotidine | Hana famotidine | Hanmi famotidine | Hawon famotidine | I motine | Imodine | Jeil famotidine | Kd fanitine | Kyungdong fanitine | Locacid | Mooter | Motin | Pamagen | Pandona | Paradine | Patidine | Pepticon | Peptidin | Peptis | Pharmbio korea famotidine | Rastine | Rp tidine | Samik famotidine | Samnam famotidine | Samsung famotidine | Spadin | Tds famotidine | Tifadine | Wihtus famotidine | Wimoticone | Yuhan famotidine | Yungjin famotidine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Famodar | Famodar Abr | Pepcidin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">APO Famotidine | Famodar Abr | Gastrodomina | Pepcidin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Famogast | Famosan | Famotidin 20-sl | Famotidin 40-sl | Gastrosidin | Quamatel | Topcid | Ulfamid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Pepcidine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Famogast | Famosan | Famotidin ratiopharm | Famotidin stada | Gastrosidin | Quamatel | Ulfamid</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Digervin | Famotid | Pepdine | Servipep | Ulcidine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amofat | Andotrin | Durater | Eufatin | Facidex | Famotidina gi | Famoxal | Farmotex | Fatoril | Ludex | Pepcidine | Sertidine | Sigafam</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dyamodil | Fadine | Famodar | Famodine | Famofast | Famopsin | Famorila | Famotin | Hovid famotidine | Pepcidine | Pepciron | Pepzan | Sunpepcin | Ulceran | Voker</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Maagzuurremmer famotidine | Pepcid | Pepcidin | Pepdine | Peptan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Famogast | Famotal | Famotidin | Famotidin gea | Famotidin genericon | Famotidin stada | Famotidine west ward | Pepcid | Pepcidin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">APO Famotidine | Famotidine hovid | Famox | Pepcid ac | Pepcidine | Pepzan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Famotidina | Pepcidine</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Famicid | Famorila | Famtine | Femostal | Gastroflux | H2 bloc | Hista Bloc | Pepcidine | Ulcefam</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Acer-od | Acicon | Acicon ad | Acidrol | Aksopep | Aladin | Amotide | Antidine | Apsin | Ardfame | Atodine | Ban-ulcer | Benson | Bepsin | Cantil | Concid | Dewrel | Dinex | Ducid | Duodin | Duonol | Efrel | Facid | Fadiphine | Fagastril | Famace | Famdin | Famed | Famid | Famitol | Famobex | Famocin | Famodin | Famodine | Famogem | Famol | Famonon | Famopep | Famoprime | Famopsin | Famorax | Famorex | Famoscot | Famosib | Famot | Famotab | Famotack | Famotid | Famotil | Famotop | Famozon | Famron | Famtaza | Famtine | Famto | Famulcer | Fanitin | Fedohit | Femas | Femme | Femoceran | Fencid | Feptic | Feptid | Flodin | Fmt | Fobert | Fomen | Fomicid | Fotel | Gastadine | Gastapil | Gastifam | Gastoch | Gastrodine | Gastrorel | Gd-cid | Gepep | Gerdin | H2 bf | H2 bloc | H2 Foz | H2f | Hiler | Hisis | Hycocid | Ispep | Jevity | Ketacid | Kid h2 | Kotidine | Link live | Litz | Loacid | Lyofam | Nencid | Neofam | No-ul | Nobar | Nocer | Nocid | Novifam | Nufam | Nytom | Optifam | Otidin | Otofam | Panalba | Pandona | Papsid | Pepcidine | Pepcimed | Pepciron | Pepdis | Pepfin | Pepgard | Pepnex | Pepnic | Peprax | Peprid | Pepti | Peptiban | Peptifam | Peptiloc | Pepton | Pharmotidin | Placid | Plivadine | Polypep | Pulfame | Qincid | Quamatel | Qucid | Recid | Reducid | Ricer | Sac | Saktodin | So fem | Tabrodine | Tagafam | Tasofam | Tifam | Tinopep | Tulip | Ul-safe | Ulcare | Ulceban | Ulcefame | Ulcemal | Ulcenil | Ulcepep | Ulceran | Ulciban | Ulcifam | Ulcofin | Ulfam | Ulfarid | Ulsamark | Ulsin | Volvic | Welcid | Welfam | Xerocid | Yamadin | Zebid | Zecid | Zepsin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo-famo | Fagastin | Famidyna | Famogast | Famotydyna ranigast | Quamatel | Ulfamid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Acid controller | Heartburn relief | Pepcid | Pepcid rpd</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dinul | Dipsin | Famotidina | Famotidina generis | Fatidin | Gastopride | Gastrifam | Lasa | Mensoma | Nulceran | Pepcidina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Gastrium | Tarpan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Apo-Famotidine | Famodar | Famodar ABR | Famotak | Famotec | Famotidine Mabo</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Famodar | Famodin | Famogast | Famosan | Famotak | Famotidina alkaloid | Famotidina fiterman | Famotidina zentiva | Gastrosidin | Quamatel | Ulceran | Ulfamid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">APO Famotidine | Blocacid | Famocid | Famonite | Famosan | Famotidin | Famotidin akri | Famotidin stada | Famotidine Akri | Gastrosidin | Quamatel | Ulfamid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Famocid | Famodar | Famogen | Pepcidin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Famotidin hexal | Pepcid</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">APO Famotidine | Blocacid | Famoc | Famocid | Famodine | Famopril | Famorila | Famotin | Famox | Febcid | Pepcidine | Pepzan | Servipep | Sunpepcin | Ulceran</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Famosin | Ulfamid</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Famosan | Famotidin | Quamatel | Ulceran | Ulfamid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fad | Fadine | Famadine | Famoc | Famocid | Famodee | Famodil | Famoflux | Famomed | Famonox | Famopsin | Famosia | Famostar | Famot | Famotab | Famotin | Famotin-f | Fanitin | Pepcidine | Pepcine | Pepdenol | Pepfamin | Pepmodine | Peptoci | Pepzan | Pharmotidine | Phartidine | Servipep | Ulfamet</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ah deux | Famodar | Famodine | Gastrosidin | Gastrozen | Pepdine | Uldine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Duovel | Famec | Famo | Famodin | Famogast | Famoser | Famotep | Famotsan | Gasterol | Gastifam | Gastover | Gastrofam | Gastrosidin | Nevofam | Notidin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fadin | Famcid | Famo | Famodine | Famoster | Famox | Famulcer | Forgas | Fuweidin | Gasafe | Gaster | Gelfos culcer | Jiawiller | Kimodin | Pepzan | Quimadine | Supertidine | Suwdfue | Suwefue | Ulstop | Voker | Weimok | Welizen | Winiful</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Famatel forte | Famocid | Famosan | Famotidin | Gastrosidin | Quamatel | Ulceran | Ulfamid</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Antiflam | Famotec | Famotidina | Famotidina opko | Famucid | Gastrofam | Pepcidine | Regulacid | Ulcelac | Ulfinol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dinamot | Fadipina | Famotidina | Famulcer | Isomina | Klinotal | Medalin | Pepcidine | Sintiabyl | Ulcenol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Facidintas | Faditac | Fatodin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Famotidine denk</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9623009">
<a name="9623009"></a>Aanpreung P, Vanprapar N, Susiva C, Parkpreaw C, Boonyachart C. A randomized clinical trial comparing the efficacy of ranitidine and famotidine on intragastric acidity in critically ill pediatric patients. <i>J Med Assoc Thai</i>. 1998;81(3):185-189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/9623009/pubmed" id="9623009" target="_blank">9623009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Abir.2022">
<a name="Abir.2022"></a>Abir G, Carvalho B. Anesthesia for nondelivery obstetric procedures. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21131924">
<a name="21131924"></a>Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. <i>Am J Gastroenterol</i>. 2010;105(12):2533-2549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/21131924/pubmed" id="21131924" target="_blank">21131924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2028638">
<a name="2028638"></a>Ahmad S. Famotidine and cardiac arrhythmia. <i>DICP</i>. 1991;25(3):315. doi:10.1177/106002809102500319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/2028638/pubmed" id="2028638" target="_blank">2028638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akin.2019">
<a name="Akin.2019"></a>Akin C, Gotlib J. Advanced systemic mastocytosis: Management and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26580836">
<a name="26580836"></a>American Society of Anesthesiologists (ASA). Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. <i>Anesthesiology</i>. 2016;124(2):270-300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/26580836/pubmed" id="26580836" target="_blank">26580836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28045707">
<a name="28045707"></a>American Society of Anesthesiologists (ASA). Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration. <i>Anesthesiology</i>. 2017;126(3):376-393. doi: 10.1097/ALN.0000000000001452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/28045707/pubmed" id="28045707" target="_blank">28045707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10690219">
<a name="10690219"></a>American Society of Health-System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. <i>Am J Health Syst Pharm</i>. 1999;56(4):347-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/10690219/pubmed" id="10690219" target="_blank">10690219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al, eds. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7712759">
<a name="7712759"></a>Baghaie AA, Mojtahedzadeh M, Levine RL, Fromm RE Jr, Guntupalli KK, Opekun AR Jr. Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients: results of a prospective, randomized, crossover study. <i>Crit Care Med</i>. 1995;23(4):687-691.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/7712759/pubmed" id="7712759" target="_blank">7712759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30680444">
<a name="30680444"></a>Barbateskovic M, Marker S, Granholm A, et al. Stress ulcer prophylaxis with proton pump inhibitors or histamine-2 receptor antagonists in adult intensive care patients: a systematic review with meta-analysis and trial sequential analysis. <i>Intensive Care Med</i>. 2019;45(2):143-158. doi: 10.1007/s00134-019-05526-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/30680444/pubmed" id="30680444" target="_blank">30680444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7917695">
<a name="7917695"></a>Behrens R, Hofbeck M, Singer H, Scharf J, Rupprecht T. Frequency of stress lesions of the upper gastrointestinal tract in paediatric patients after cardiac surgery: effects of prophylaxis. <i>Br Heart J</i>. 1994;72(2):186-189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/7917695/pubmed" id="7917695" target="_blank">7917695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berkow.2019">
<a name="Berkow.2019"></a>Berkow L. Rapid sequence induction and intubation (RSII) for anesthesia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 23, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24766875">
<a name="24766875"></a>Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. <i>J Allergy Clin Immunol</i>. 2014;133(5):1270-1277. doi: 10.1016/j.jaci.2014.02.036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/24766875/pubmed" id="24766875" target="_blank">24766875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8555043">
<a name="8555043"></a>Brunner M, Vardarman E, Goldermann R, et al. Toxic epidermal necrolysis (Lyell syndrome) following famotidine administration. <i>Br J Dermatol</i>. 1995;133(5):814-815. doi:10.1111/j.1365-2133.1995.tb02765.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/8555043/pubmed" id="8555043" target="_blank">8555043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16651285">
<a name="16651285"></a>Canani RB, Cirillo P, Roggero P, et al; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. <i>Pediatrics</i>. 2006;117(5):e817-e820. doi: 10.1542/peds.2005-1655<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/16651285/pubmed" id="16651285" target="_blank">16651285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1674198">
<a name="1674198"></a>Cantú TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. <i>Ann Intern Med</i>. 1991;114(12):1027-1034. doi:10.7326/0003-4819-114-12-1027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/1674198/pubmed" id="1674198" target="_blank">1674198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Castells.2019.a">
<a name="Castells.2019.a"></a>Castells MC, Akin C. Treatment and prognosis of cutaneous mastocytosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 15, 2019a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Castells.2019.b">
<a name="Castells.2019.b"></a>Castells MC, Matulonis UA, Horton TM. Infusion reactions to systemic chemotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 10, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8701013">
<a name="8701013"></a>Catalano G, Catalano MC, Alberts VA. Famotidine-associated delirium. A series of six cases. <i>Psychosomatics</i>. 1996;37(4):349-355. doi:10.1016/S0033-3182(96)71548-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/8701013/pubmed" id="8701013" target="_blank">8701013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22273212">
<a name="22273212"></a>Compoginis JM, Gaspard D, Obaid A. Famotidine use and thrombocytopenia in the trauma patient. <i>Am Surg</i>. 2011;77(12):1580-1583.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/22273212/pubmed" id="22273212" target="_blank">22273212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3207568">
<a name="3207568"></a>Courtney, TP, Shaw RW, Cedar E, et al, "Excretion of Famotidine in Breast Milk," Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts. <i>Br J Clin Pharmacol</i>, 1988;26(5):639P.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/3207568/pubmed" id="3207568" target="_blank">3207568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1764869">
<a name="1764869"></a>Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. <i>Clin Pharmacokinet</i>. 1991;21(3):178-194. doi:10.2165/00003088-199121030-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/1764869/pubmed" id="1764869" target="_blank">1764869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15557833">
<a name="15557833"></a>Ecker RD, Wijdicks EF, Wix K, McClelland R. Does famotidine induce thrombocytopenia in neurosurgical patients? <i>J Neurosurg Anesthesiol</i>. 2004;16(4):291-293. doi:10.1097/00008506-200410000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/15557833/pubmed" id="15557833" target="_blank">15557833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29915158">
<a name="29915158"></a>Eichenwald EC; AAP Committee on Fetus and Newborn. Diagnosis and management of gastroesophageal reflux in preterm infants. <i>Pediatrics</i>. 2018;142(1):e20181061. doi:10.1542/peds.2018-1061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/29915158/pubmed" id="29915158" target="_blank">29915158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Athenex.1">
<a name="Athenex.1"></a>Famotidine injection [prescribing information]. Schaumburg, IL: Athenex; July 2020.</div>
</li>
<li>
<div class="reference">
                  Famotidine oral suspension [prescribing information]. Memphis, TN: Northstar Rx LLC; June 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/northstar.1/pubmed" id="northstar.1" target="_blank">northstar.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-baxter.1">
<a name="baxter.1"></a>Famotidine premixed injection in Galaxy plastic container [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-fass.2019">
<a name="fass.2019"></a>Fass R. Approach to refractory gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2902874">
<a name="2902874"></a>Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glöckner WM, Mann H. Pharmacokinetics and dynamics of famotidine in patients with renal failure. <i>Br J Clin Pharmacol</i>. 1988;26(3):315-321. doi:10.1111/j.1365-2125.1988.tb05282.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/2902874/pubmed" id="2902874" target="_blank">2902874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4030706">
<a name="4030706"></a>Goff DC, Garber HJ, Jenike MA. Partial resolution of ranitidine-associated delirium with physostigmine: case report. <i>J Clin Psychiatry</i>. 1985;46(9):400-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/4030706/pubmed" id="4030706" target="_blank">4030706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29019150">
<a name="29019150"></a>Guarnotta V, Martini C, Davì MV, Pizza G, Colao A, Faggiano A; NIKE Group. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? <i>Endocrine</i>. 2018;60(1):15-27. doi:10.1007/s12020-017-1420-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/29019150/pubmed" id="29019150" target="_blank">29019150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16390920">
<a name="16390920"></a>Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. <i>Pediatrics.</i> 2006;117(2):137-142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/16390920/pubmed" id="16390920" target="_blank">16390920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19173722">
<a name="19173722"></a>Gupta N, Patel C, Panda M. Hepatitis following famotidine: a case report. <i>Cases J</i>. 2009;2(1):89. doi:10.1186/1757-1626-2-89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/19173722/pubmed" id="19173722" target="_blank">19173722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23254444">
<a name="23254444"></a>Gupta RW, Tran L, Norori J, et al. Histamine-2 receptor blockers alter the fecal microbiota in premature infants. <i>J Pediatr Gastroenterol Nutr</i>. 2013;56(4):397-400. doi:10.1097/MPG.0b013e318282a8c2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/23254444/pubmed" id="23254444" target="_blank">23254444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hagberg.2019">
<a name="Hagberg.2019"></a>Hagberg CA, Artime C. Flexible scope intubation for anesthesia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3243179">
<a name="3243179"></a>Henann NE, Carpenter DU, Janda SM. Famotidine-associated mental confusion in elderly patients. <i>Drug Intell Clin Pharm</i>. 1988;22(12):976-978. doi:10.1177/106002808802201209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/3243179/pubmed" id="3243179" target="_blank">3243179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9794575">
<a name="9794575"></a>Hirayama K, Hanatsuka K, Ikeuchi T, et al. Famotidine-induced acute interstitial nephritis. <i>Nephrol Dial Transplant</i>. 1998;13(10):2636-2638. doi:10.1093/ndt/13.10.2636<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/9794575/pubmed" id="9794575" target="_blank">9794575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000; 343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23363383">
<a name="23363383"></a>Ito T, Igarashi H, Uehara H, Jensen RT. Pharmacotherapy of Zollinger-Ellison syndrome. <i>Expert Opin Pharmacother</i>. 2013;14(3):307-321. doi:10.1517/14656566.2013.767332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/23363383/pubmed" id="23363383" target="_blank">23363383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8853932">
<a name="8853932"></a>James LP and Kearns GL, “Pharmacokinetics and Pharmacodynamics of Famotidine in Paediatric Patients,” <i>Clin Pharmacokinet</i>, 1996, 31(2):103-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/8853932/pubmed" id="8853932" target="_blank">8853932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11301560">
<a name="11301560"></a>James LP, Marotti T, Stowe CD, et al, "Pharmacokinetics and Pharmacodynamics of Famotidine in Infants," <i>J Clin Pharmacol</i>, 1998, 38(12):1089-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/11301560/pubmed" id="11301560" target="_blank">11301560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-kahn.2019">
<a name="kahn.2019"></a>Kahn DA. Chronic spontaneous urticaria: Standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-kahrilas.2020">
<a name="kahrilas.2020"></a>Kahrilas PJ. Medical management of gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34807007">
<a name="34807007"></a>Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/34807007/pubmed" id="34807007" target="_blank">34807007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23419381">
<a name="23419381"></a>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease [published correction appears in <i>Am J Gastroenterol</i>. 2013;108(10):1672]. <i>Am J Gastroenterol</i>. 2013;108(3):308-328. doi: 10.1038/ajg.2012.444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/23419381/pubmed" id="23419381" target="_blank">23419381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kellner.2019">
<a name="Kellner.2019"></a>Kellner C. Technique for performing electroconvulsive therapy (ECT) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 6, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20461973">
<a name="20461973"></a>Kim YI, Park CK, Park DJ, Wi JO, Han ER, Koh YI. A case of famotidine-induced anaphylaxis. <i>J Investig Allergol Clin Immunol</i>. 2010;20(2):166-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/20461973/pubmed" id="20461973" target="_blank">20461973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2311331">
<a name="2311331"></a>Kraus G, Krishna DR, Chmelarsch D, Schmid M, Klotz U. Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery. <i>Clin Pharmacokinet</i>. 1990;18(1):77-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/2311331/pubmed" id="2311331" target="_blank">2311331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27690471">
<a name="27690471"></a>Kulthanan K, Tuchinda P, Chularojanamontri L, et al. Clinical practice guideline for diagnosis and management of urticaria. <i>Asian Pac J Allergy Immunol</i>. 2016;34(3):190-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/27690471/pubmed" id="27690471" target="_blank">27690471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929377">
<a name="33929377"></a>Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. <i>Am J Gastroenterol</i>. 2021;116(5):899-917. doi:10.14309/ajg.0000000000001245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/33929377/pubmed" id="33929377" target="_blank">33929377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24327038">
<a name="24327038"></a>Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/24327038/pubmed" id="24327038" target="_blank">24327038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28242110">
<a name="28242110"></a>Lanas A, Chan FKL. Peptic ulcer disease. <i>Lancet</i>. 2017;390(10094):613-624. doi: 10.1016/S0140-6736(16)32404-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/28242110/pubmed" id="28242110" target="_blank">28242110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19240698">
<a name="19240698"></a>Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. <i>Am J Gastroenterol</i>. 2009;104(3):728-738.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/19240698/pubmed" id="19240698" target="_blank">19240698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15135720">
<a name="15135720"></a>Lee KW, Kayser SR, Hongo RH, Tseng ZH, Scheinman MM. Famotidine and long QT syndrome. <i>Am J Cardiol</i>. 2004;93(10):1325-1327. doi:10.1016/j.amjcard.2004.02.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/15135720/pubmed" id="15135720" target="_blank">15135720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7739945">
<a name="7739945"></a>Lipsy R, Freeman CD. Hemodynamic Effects of Intravenous Famotidine in Critically Ill Patients. <i>Pharmacotherapy. </i>1995;15(1):48-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/7739945/pubmed" id="7739945" target="_blank">7739945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6377973">
<a name="6377973"></a>Manchikanti L, Marrero TC, Roush JR. Preanesthetic cimetidine and metoclopramide for acid aspiration prophylaxis in elective surgery. <i>Anesthesiology</i>. 1984;61(1):48-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/6377973/pubmed" id="6377973" target="_blank">6377973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12520622">
<a name="12520622"></a>Maples HD, James LP, Stowe CD, et al. Famotidine disposition in children and adolescents with chronic renal insufficiency. <i>J Clin Pharmacol</i>. 2003;43(1):7-14. doi:10.1177/0091270002239700<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/12520622/pubmed" id="12520622" target="_blank">12520622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11847947">
<a name="11847947"></a>Marcus EL, Clarfield AM, Kleinman Y, Bits H, Darmon D, Da'as N. Agranulocytosis associated with initiation of famotidine therapy. <i>Ann Pharmacother</i>. 2002;36(2):267-271. doi:10.1345/aph.1A045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/11847947/pubmed" id="11847947" target="_blank">11847947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2872952">
<a name="2872952"></a>McCammon RL. Prophylaxis for aspiration pneumonitis. <i>Can Anaesth Soc J</i>. 1986;33(3, pt 2):s47-s53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/2872952/pubmed" id="2872952" target="_blank">2872952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30032223">
<a name="30032223"></a>Miller JW. Proton pump inhibitors, H2-receptor antagonists, metformin, and vitamin B-12 deficiency: clinical implications. <i>Adv Nutr</i>. 2018;9(4):511S-518S. doi:10.1093/advances/nmy023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/30032223/pubmed" id="30032223" target="_blank">30032223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nixon.2019">
<a name="Nixon.2019"></a>Nixon H, Leffert L. Anesthesia for cesarean delivery. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7148360">
<a name="7148360"></a>Olsson GL, Hallén B. Pharmacological evacuation of the stomach with metoclopramide. <i>Acta Anaesthesiol Scand</i>. 1982;26(5):417-420.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/7148360/pubmed" id="7148360" target="_blank">7148360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20562638">
<a name="20562638"></a>O'Reardon JP, Cristancho MA, von Andreae CV, Cristancho P, Weiss D. Acute and maintenance electroconvulsive therapy for treatment of severe major depression during the second and third trimesters of pregnancy with infant follow-up to 18 months: case report and review of the literature. <i>J ECT</i>. 2011;27(1):e23-e26. doi: 10.1097/YCT.0b013e3181e63160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/20562638/pubmed" id="20562638" target="_blank">20562638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12752346">
<a name="12752346"></a>Orenstein SR, Shalaby TM, Devandry SN, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. <i>Aliment Pharmacol Ther</i>. 2003;17(9):1097-1107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/12752346/pubmed" id="12752346" target="_blank">12752346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8193440">
<a name="8193440"></a>Oymak O, Akpolat T, Arik N, Yasavul U, Turgan C, Caglar S. Reversible neutropenia and thrombocytopenia during famotidine treatment. <i>Ann Pharmacother</i>. 1994;28(3):406-407. doi:10.1177/106002809402800326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/8193440/pubmed" id="8193440" target="_blank">8193440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-pepcid.1">
<a name="pepcid.1"></a>Pepcid (famotidine powder for suspension) [prescribing information]. Minneapolis, MN: Perrigo; June 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-pepcid.2">
<a name="pepcid.2"></a>Pepcid AC (famotidine) [prescribing information]. Fort Washington, PA: McNeil Consumer; received April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-pepcid.3">
<a name="pepcid.3"></a>Pepcid AC Maximum Strength (famotidine) [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare; received February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-pepcid.4">
<a name="pepcid.4"></a>Pepcid (famotidine) tablets [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19358226">
<a name="19358226"></a>Poluzzi E, Raschi E, Moretti U, et al. Drug-Induced Torsades de Pointes: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS). <i>Pharmacoepidemiol Drug Saf.</i> 2009;18(6):512-518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/19358226/pubmed" id="19358226" target="_blank">19358226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11692973">
<a name="11692973"></a>Rabheru K. The use of electroconvulsive therapy in special patient populations. <i>Can J Psychiatry</i>. 2001;46(8):710-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/11692973/pubmed" id="11692973" target="_blank">11692973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30101529">
<a name="30101529"></a>Reynolds PM, MacLaren R. Re-evaluating the utility of stress ulcer prophylaxis in the critically ill patient: a clinical scenario-based meta-analysis [published online ahead of print August 13, 2018]. <i>Pharmacotherapy</i>. doi: 10.1002/phar.2172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/30101529/pubmed" id="30101529" target="_blank">30101529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16225482">
<a name="16225482"></a>Richter JE. Review article: the management of heartburn in pregnancy. <i>Aliment Pharmacol Ther</i>. 2005;22(9):749-757. doi: 10.1111/j.1365-2036.2005.02654.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/16225482/pubmed" id="16225482" target="_blank">16225482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9545163">
<a name="9545163"></a>Rodgers PT, Brengel GR. Famotidine-associated mental status changes. <i>Pharmacotherapy</i>. 1998;18(2):404-407.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/9545163/pubmed" id="9545163" target="_blank">9545163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27390109">
<a name="27390109"></a>Romaine A, Ye D, Ao Z, et al. Safety of histamine-2 receptor blockers in hospitalized VLBW infants. <i>Early Hum Dev</i>. 2016;99:27-30. doi:10.1016/j.earlhumdev.2016.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/27390109/pubmed" id="27390109" target="_blank">27390109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11525610">
<a name="11525610"></a>Rudolph CD, Mazur LJ, Liptak GS, et al, "Guidelines for Evaluation and Treatment of Gastroesophageal Reflux in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition," <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(Suppl 2):1-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/11525610/pubmed" id="11525610" target="_blank">11525610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2312768">
<a name="2312768"></a>Saima S, Echizen H, Yoshimoto K, Ishizaki T. Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients. <i>J Clin Pharmacol</i>. 1990;30(2):159-162. doi:10.1002/j.1552-4604.1990.tb03456.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/2312768/pubmed" id="2312768" target="_blank">2312768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30947259">
<a name="30947259"></a>Santos VS, Freire MS, Santana RNS, Martins-Filho PRS, Cuevas LE, Gurgel RQ. Association between histamine-2 receptor antagonists and adverse outcomes in neonates: a systematic review and meta-analysis. <i>PLoS One</i>. 2019;14(4):e0214135. doi:10.1371/journal.pone.0214135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/30947259/pubmed" id="30947259" target="_blank">30947259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9952172">
<a name="9952172"></a>Schoenwald PK, Sprung J, Abdelmalak B, Mraović B, Tetzlaff JE, Gurm HS. Complete atrioventricular block and cardiac arrest following intravenous famotidine administration. <i>Anesthesiology</i>. 1999;90(2):623-626. doi:10.1097/00000542-199902000-00040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/9952172/pubmed" id="9952172" target="_blank">9952172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8694150">
<a name="8694150"></a>Stuart JC, Kan AF, Rowbottom SJ, Yau G, Gin T. Acid aspiration prophylaxis for emergency Caesarean section. <i>Anaesthesia</i>. 1996;51(5):415-421.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/8694150/pubmed" id="8694150" target="_blank">8694150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2861096">
<a name="2861096"></a>Takabatake T, Ohta H, Maekawa M, et al. Pharmacokinetics of famotidine, a new H<sub>2</sub>-receptor antagonist, in relation to renal function. <i>Eur J Clin Pharmacol</i>. 1985;28(3):327-331. doi:10.1007/BF00543332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/2861096/pubmed" id="2861096" target="_blank">2861096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22157140">
<a name="22157140"></a>Terrin G, Passariello A, De Curtis M, et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. <i>Pediatrics</i>. 2012;129(1):e40-e45. doi:10.1542/peds.2011-0796<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/22157140/pubmed" id="22157140" target="_blank">22157140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16222731">
<a name="16222731"></a>Tomassetti P, Campana D, Piscitelli L, et al. Treatment of Zollinger-Ellison syndrome. <i>World J Gastroenterol</i>. 2005;11(35):5423-5432. doi:10.3748/wjg.v11.i35.5423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/16222731/pubmed" id="16222731" target="_blank">16222731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2019939">
<a name="2019939"></a>Treem WR, Davis PM, Hyams JS. Suppression of Gastric Acid Secretion by Intravenous Administration of Famotidine in Children. <i>J Pediatr.</i> 1991;118(5):812-816.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/2019939/pubmed" id="2019939" target="_blank">2019939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-vakil.2019">
<a name="vakil.2019"></a>Vakil NB. Peptic ulcer disease: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429582">
<a name="24429582"></a>van der Woude CJ, Metselaar HJ, Danese S. Management of gastrointestinal and liver diseases during pregnancy. <i>Gut</i>. 2014;63(6):1014-1023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/24429582/pubmed" id="24429582" target="_blank">24429582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12163986">
<a name="12163986"></a>von Einsiedel RW, Roesch-Ely D, Diebold K, Sartor K, Mundt C, Bergemann N. H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures. <i>Pharmacopsychiatry</i>. 2002;35(4):152-154. doi:10.1055/s-2002-33193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/12163986/pubmed" id="12163986" target="_blank">12163986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11967601">
<a name="11967601"></a>Wade EE, Rebuck JA, Healey MA, Rogers FB. H(2) antagonist-induced thrombocytopenia: is this a real phenomenon? <i>Intensive Care Med</i>. 2002;28(4):459-465. doi:10.1007/s00134-002-1233-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/11967601/pubmed" id="11967601" target="_blank">11967601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19821323">
<a name="19821323"></a>Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. <i>Cochrane Database Syst Rev</i>. 2009;(4):CD004275. doi: 10.1002/14651858.CD004275.pub3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/19821323/pubmed" id="19821323" target="_blank">19821323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23401067">
<a name="23401067"></a>Wang X, Rytting E, Abdelrahman DR, Nanovskaya TN, Hankins GD, Ahmed MS. Quantitative determination of famotidine in human maternal plasma, umbilical cord plasma and urine using high-performance liquid chromatography-mass spectrometry. <i>Biomed Chromatogr</i>. 2013;27(7):866-873.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/23401067/pubmed" id="23401067" target="_blank">23401067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-wang.2011">
<a name="wang.2011"></a>Wang X, Zhan Y, Hankins GD et al. Pharmacokinetics of famotidine in pregnant women. <i>Am J Obstet Gynecol</i>. 2011;204:S72-S73.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weinhouse.2022">
<a name="Weinhouse.2022"></a>Weinhouse GL. Stress ulcer in the intensive care unit: Diagnosis, management, and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15828852">
<a name="15828852"></a>Wenning LA, Murphy MG, James LP, et al, "Pharmacokinetics of Famotidine in Infants," <i>Clin Pharmacokinet</i>, 2005, 44(4):395-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/15828852/pubmed" id="15828852" target="_blank">15828852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22584954">
<a name="22584954"></a>Wu CS, Sung SF, Tong SH, Ong CT. Multiple cerebral infarctions related to famotidine-induced eosinophilia. <i>J Neurol</i>. 2012;259(10):2229-2231. doi:10.1007/s00415-012-6534-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/22584954/pubmed" id="22584954" target="_blank">22584954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8004885">
<a name="8004885"></a>Yoshimoto K, Saima S, Echizen H, et al. Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure. <i>Clin Pharmacol Ther</i>. 1994;55(6):693-700. doi:10.1038/clpt.1994.86<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/8004885/pubmed" id="8004885" target="_blank">8004885</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13295 Version 779.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
